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It is well known that G6PD-deﬁcient individuals are highly susceptible to oxidative stress. However, the diﬀerences in the degree of
metabolic alterations among patients during an oxidative crisis have not been extensively studied. In this study, we applied mathe-
matical modeling to assess the metabolic changes in erythrocytes of various G6PD-deﬁcient patients during hydrogen peroxide-
(H2O2-) induced perturbation and predict the kinetic properties that elicit redox imbalance after exposure to an oxidative agent.
Simulation results showed a discrepancy in the ability to restore regular metabolite levels and redox homeostasis among patients.
Two trends were observed in the response of redox status (GSH/GSSG) to oxidative stress, a mild decrease associated with slow
recovery and a drastic decline associated with rapid recovery. The former was concluded to apply to patients with severe clinical
symptoms. Low Vmax and high KmG6P of G6PD were shown to be kinetic properties that enhance consequent redox imbalance.
1.Introduction
Glucose-6-phosphate dehydrogenase (G6PD) deﬁciency, an
X-chromosomelinkedgeneticdisorder,isthemostprevalent
mutation in humans aﬀecting more than 400 million people
worldwide [1–4]. It is characterized by the decreased activity
of the G6PD enzyme, which is the central factor of the
antioxidant defense system in erythrocytes (or RBCs). The
enzyme is responsible for maintaining the high levels of
reduced glutathione (GSH) and nicotine adenine dinu-
cleotide phosphate (NADPH) that protect the cell from oxi-
dative damage caused by harmful reactive oxygen species
(ROS).
As RBCs are unable to generate NADPH through other
pathways [5, 6], G6PD-deﬁcient RBCs lack the ability to tol-
erate excessive amounts of oxidative stress [7–9]. The most
common clinical manifestation associated with G6PD deﬁ-
ciency is hemolytic anemia, which is generally triggered by
the intake of oxidative drugs or foods [5, 10]. At times, the
defect can result in complications such as kidney failure,
severe neonatal jaundice, gallstones, and may require blood
transfusion [2, 9–11].
The clinical consequences of drug-induced G6PD deﬁ-
ciency-related hemolysis depend on several factors including
the kinetic properties of the G6PD variant. Commonly the
diagnosis of patients is performed by a rapid ﬂuorescent
spot test of NADPH generation [12, 13] and a quantita-
tive spectrophotometric assay of G6PD activity [10, 14].
Although these tests provide us with some perspective on
the degree of severity of a patient’s clinical symptoms, they
are based on measurements of G6PD-speciﬁc activity when
a patient is under normal conditions, and do not speciﬁcally
predict the dynamic response of metabolite and enzyme
activity levels in a patient’s RBCs during the intake of oxi-
dativeagents.Moreover,carryingoutthetestduringanacute
hemolytic episode would give unreliable results, as the activ-
ity of the abnormal G6PD-deﬁcient cells would be obscured
by the large population of reticulocytes having relatively
higher enzyme activities than the fully matured RBCs [9, 10,
15]. Consequently, the preclinical assessment of sensitivity2 Advances in Hematology
to oxidative stress in individual G6PD-deﬁcient patients
through in vivo experiments remains a diﬃcult task [16–18].
In this study, we apply mathematical modeling to assess the
changes in antioxidant enzyme activities and redox status
for various individuals with G6PD deﬁciency during acute
exposure to an oxidative agent. The main objective of this
paper is to study the diﬀerences in the metabolic alter-
ations during drug-induced hemolytic conditions in G6PD-
deﬁcient patients and predict the kinetic properties that
enhance the degree of redox imbalance after an oxidative
crisis.
Drug interaction in RBCs is known to produce hydrogen
peroxide (H2O2) directly or by way of ROS [9]. We therefore
expanded an existing model of human RBC metabolism
[19] to include the component reactions of ROS production
and their removal processes. By inputting parameters of
G6PD-deﬁcient patients into this model, we performed
simulation experiments to assess the metabolic response
during exposure to oxidative H2O2 in patients’ RBCs. We
designated indicators of redox imbalance (e.g., recovery time
ofGSH/GSSG)fromresultantsimulationdatatoevaluatethe
relationship between kinetic parameters for the G6PD reac-
tion in the patient’s RBC and the patient’s ability to recover
from the transient oxidative perturbation. The targets of
our simulation included the RBCs of 10 G6PD-deﬁcient
patientsbasedonrealdata(Table 1,[21]),andvirtualG6PD-
deﬁcient patients composed of randomly chosen kinetic pa-
rameters. The results of these experiments predicted the
kinetic properties of G6PD that make a patient suﬀer major
alterationsin redox homeostasis afteranoxidative crisis. Our
simulation results provide insights for improved patient-
level treatment through the mathematical modeling and
simulation of symptomatic situations, as well as a better un-
derstanding of the pathophysiology of G6PD deﬁciency.
2.MaterialsandMethods
The experimental workﬂow is presented schematically in
Figure 1.
2.1. Representation of the Antioxidant System Using a Math-
ematical Model. A published model of human RBC metab-
olism [19] constructed in E-Cell System Environment Ver-
sion 3 (E-Cell, [22, 23]) was used as a basis for the construc-
tion of our model of the oxidative stress removal mechanism
in RBCs. The model is built up of major metabolic pathways
including glycolysis, pentose phosphate pathway, adenine
nucleotide metabolism, glutathione metabolism, several
membrane transport systems, ion leakage processes, Na+/K+
pump, and binding reactions of metabolites to Mg2+ and
hemoglobin. The rate equations are derived from previous
experimental data and are described in the Supplementary
Material (see Supplementary Material available online at doi:
10.1155/2011/398945).
In the developed model (Figure 2), we incorporated the
diﬀusionofH2O2 intotheRBCandthegenerationofO2
−,as
well as their removal processes catalyzed by the antioxidants
catalase (CAT), superoxide dismutase (SOD), and gluta-
thione peroxidase (GSHpx). Detailed descriptions of the
enzymatic equations and initial parameter values can be
viewed in the Supplementary Material.
2.2. Adjustment of Kinetic Parameters to Represent Individual
Patients. The reaction catalyzed by the G6PD enzyme and
the reaction rate (ν) are expressed by the following equa-
tions (G6P, glucose-6-phosphate; GL6P, gluconolactone-6-
phosphate, 2,3BPG, 2,3-bisphosphoglycerate):
G6P +NADP −→ GL6P +NADPH,
ν=
Vmax
[NADP][G6P]
KmNADPKmG6P
1+
[NADP]
KmNADP

1+
[G6P]
KmG6P

+
[NADPH]
KiNADPH
+
[ATP]
KiATP
+
[2,3BPG]
Ki2, 3BPG
,
(1)
where Vmax represents the maximum initial velocity of the
reaction, and Km and Ki stand for the concentration of sub-
strate that produces half-maximal velocity and inhibitor
constant, respectively.
When building RBC models for simulation of individual
patients, the parameters Vmax, KmG6P, KmNADP, KiNADPH,
KiATP,a n dKi2,3BPG were ﬁt to the values speciﬁc to each
patient. We ﬁrst used parameter data from a previous study
[21] to model 10 real G6PD-deﬁcient patients and one
healthy control. The hematological and kinetic parameters
of the patients diﬀered signiﬁcantly (Table 1). Under the as-
sumption that it would be diﬃcult to predict the trends in
the relationship between patients’ kinetic parameters and
their ability to restore steady state conditions after oxidative
perturbation from the limited experimental data alone, we
created virtual patients with these 6 parameters randomly
chosen from a range of realistic values (Table 2), which
ranged from the minimum to maximum values of the real
patient parameter set (Table 1). Data for 500 virtual patients
was obtained in each trial run.
2.3. Insertion of H2O2 Perturbation. To assess the dynamical
response of the metabolic network of the RBCs during expo-
sure to sudden high levels of oxidative stress, we ﬁrst devel-
oped a model representing metabolic steady state and then
added a perturbation of 0.1mM of H2O2 (Figure 1(c)). The
behavior over time of the ratio of reduced glutathione to
oxidized glutathione (GSH/GSSG) and the ratio of reduced
nicotinamide adenine dinucleotide phosphate to nicoti-
namide adenine dinucleotide phosphate (NADPH/NADP),
aswellastheenzymaticactivityofG6PD,CAT,andGSHpxin
each patient were investigated. We then calculated the GSH/
GSSG at steady state, the time required for GSH/GSSG to
return to the normal level after the perturbation, and the
amount of change in GSH/GSSG during the perturbation
to evaluate the potential of oxidative stress-induced redox
imbalance (Figure 1(d), [24]). Henceforth, these indicators
will be referred to as “initial GSH/GSSG,” “recovery time,”
and “amount of change,” respectively. In the calculation of
amount of change, we used the following equation:
Amount of change=
[GSH]/[GSSG]ss−[GSH]/[GSSG]min
[GSH]/[GSSG]ss
,
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Table 1: Hematological and kinetic parameters of G6PD-deﬁcient patients (obtained from [19, 20]).
Patient Reticulocytes (%) Half-life (days) Vmax (M/s) KmG6P (µM) KmNADP (µM) KiNADP (µM) KiATP (µM) Ki2,3BPG (µM)
Patient 1 40 2.5 1.1 152 3.8 0.62 180 520
Patient 2 2 — 36.7 140 115 33.6 4687 8515
Patient 3 2 22.5 0.8 7 4.1 8.9 952 1071
Patient 4 22 — 0.8 43 155 56 11000 35000
Patient 5 2 20.0 37.1 57 30.5 3.7 5016 5507
Patient 6 15 7.2 14.5 66 3.5 1.1 212 532
Patient 7 10 — 8.9 80 3.6 1 125 586
Patient 8 4 — 0.8 68 1.4 0.9 500 2000
Patient 9 30 5.0 0.6 40 4.8 6.9 314 3784
Patient 10 15 — 18.9 79 3 4.1 407 2200
Control 1 27 64 67 3.7 3.1 749 2289
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Figure 1:Schematicrepresentationoftheexperimentalworkﬂow.(a)Weﬁrstconstructedamathematicalmodelofthehumanredbloodcell
(RBC) incorporating the antioxidant defense mechanism. (b) We then used published data from Jacobasch et al. [21] and ﬁtted the patient-
speciﬁc enzymatic kinetic parameters to build glucose-6-dehydrogenase phosphate (G6PD)-deﬁcient patient models. Concurrently, we
created virtual patient models. (c) The metabolic response of metabolite ratios and enzymatic activity to hydrogen peroxide (H2O2)
perturbation was simulated. (d) Recovery time and amount of change of the ratio of reduced glutathione to glutathione ratio (GSH/GSSG)
were used for evaluation of patient recovering ability. (e) The relationship between kinetic parameters and the indicators of redox imbalance
were examined in both real and virtual patients. (f) The kinetic properties of G6PD-deﬁcient patients with severe symptoms were predicted
from analysis results.
Table 2: Vmax and kinetic constants of enzymatic reactions in
virtual patients’ RBCs.
Proband Range of randomly chosen values
Vmax 1–64 (M/s)
KmG6P 7–152 (µM)
KmNADP 3–155 (µM)
KiNADPH 1–56 (µM)
KIATP 125–11000 (µM)
Ki2,3BPG 520–35000 (µM)
where [GSH]/[GSSG]ss represents the initial GSH/GSSG,
and [GSH]/[GSSG]min represents the minimum level of
GSH/GSSG during the observation period following the
perturbation.
2.4. Analysis of Simulation Data. From the simulation
results, we examined the relationship of initial GSH/GSSG,
recovery time and amount of change with each kinetic pa-
rameter (Vmax, KmG6P, KmNADP, KiNADPH, KiATP, Ki2,3BPG)o f
real G6PD patients and then performed the same analysis
with the virtual patients. With these results, we plotted
the values of the three indicators of redox imbalance in
accordance to Vmax and KmG6P in a 3-dimensional (3D) plot
to investigate the kinetic conditions that exhibit severe alter-
ations in redox homeostasis when exposed to an oxidative
agent.4 Advances in Hematology
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Figure 2:Apathwaymapofhumanredbloodcellmetabolismandantioxidantmechanism.ThemapispartiallyderivedfromKinoshitaetal.
[19]. Gray boxes represent metabolites, and black boxes represent membrane transport or ion pump systems. Gray font indicates enzymes,
and red font indicates the substrates or allosteric eﬀectors of glycolytic enzymes. The blue region indicates the newly added pathway of
reactive oxygen species (ROS) production and detoxiﬁcation. Deﬁnitions of abbreviations for enzymes and metabolites can be found in the
Supplementary Material.
3. Results
3.1. Metabolic Behavior of G6PD-Deﬁcient RBCs during H2O2
Perturbation. The levels of GSH/GSSG and NADPH/NADP
and the activity of G6PD, CAT, and GSHpx during sudden
exposure to a high concentration of H2O2 were traced using
the simulation model (Supplementary Figure 1). Substantial
diﬀerences in the behavior of GSH/GSSG, NADPH/NADP,
and G6PD activity in response to the input of H2O2 were
observed among the patients. Patients 1, 4, and 8 showed the
mostdistinctiveresultswhencomparedtothecontrolsubject
and other patients. The proﬁles of CAT and GSHpx activities
were identical in all patients, but CAT activity increased to
ag r e a t e rd e g r e e .
AcomparisonoftheredoxstatusindicatorGSH/GSSGin
the healthy control and patient 1 is exhibited in Figure 3.T h e
GSH/GSSG of patient 1 decreased only slightly during the
oxidativeperturbation;however,ittookarelativelylongtime
to return to the initial GSH/GSSG. In contrast, in the healthy
control, GSH/GSSG levels dropped rapidly and returned
to normal levels after a short period of time (Figure 3,
Supplementary Figure1).
3.2. Evaluation of GSH/GSSG Behavior. As mentioned previ-
ously, simulation results showed that the ability to recover
from the sudden oxidative load varied among patients, in
terms of recovery time and the amount of change. Therefore,
in addition to initial values of GSH/GSSG, recovery time and
amount of change were used to evaluate the degree of redox
imbalance following oxidative stress perturbation in patients
(Table 3).
The resistance of RBCs to oxidative stress did not seem
to correlate with a single kinetic parameter, such as Vmax of
the G6PD reaction as can be seen in patients 3, 4, and 8,
which, despite having the same Vmax, presented distinctive
recovery behavior. The healthy control had the highest initial
GSH/GSSG and shortest recovery time, and patients 1, 4,
and 8 who required long periods of time for recovery had
thelowestinitialGSH/GSSG(Table 3);patient1exhibitedan
abnormal recovery time in that the GSH/GSSG ratio did not
return to the initial level during the period of observation.
Overall, initial GSH/GSSG was proportional to the amount
of change during the perturbation (correlation coeﬃcient
R = 0.99), and recovery time was inversely proportional to
amount of change (R = 0.91, Supplementary Figure 2).Advances in Hematology 5
Table 3: GSH/GSSG behavior of G6PD-deﬁcient patients.
Proband Vmax (M/s) Initial [GSH]/[GSSG] Recovery time (s) Amount of change (ratio)
Patient 1 1.1 209.04 — 0.07
Patient 2 36.7 666.76 279.21 0.19
Patient 3 0.8 692.25 254.31 0.20
Patient 4 0.8 388.00 552.41 0.12
Patient 5 37.1 680.83 289.74 0.19
Patient 6 14.5 675.73 272.29 0.19
Patient 7 8.9 642.44 286.27 0.19
Patient 8 0.8 515.93 398.94 0.16
Patient 9 0.6 585.01 314.17 0.17
Patient 10 18.9 696.04 275.23 0.20
Control 64 700.38 235.52 0.20
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Figure 3: Comparison of the behavior of GSH/GSSG in the healthy
control and patient 1 during H2O2 perturbation. 0.1mM of H2O2
was added at 0 min, and the simulation was run for approximately
30min. The y-axis represents the ratio of [GSH]/[GSSG] relative to
the initial ratio, which is set as 1.0. The ﬁgure compares the healthy
subject with the patient with the longest recovery time in the set of
patients (i.e., patient 1).
3.3. Eﬀects of Kinetic Parameters on Antioxidant Capacity.
Simulation results of steady state GSH/GSSG, recovery time,
and amount of change were plotted against the Vmax, KmG6P,
KmNADP, KiNADPH, KiATP,a n dKi2,3BPG of real G6PD patients
(SupplementaryFigure 3);equivalentplotswereconstructed
for virtual patients (Supplementary Figure 4). Of these 6
parameters, Vmax and KmG6P showed the highest association
with the indicators of redox imbalance (Supplementary
Figures 3 and 4); this trend was more obvious in the data
for virtual patients than real patients because of the larger
number of virtual patients.
The distribution of plots for initial GSH/GSSG and
amount of change were similar in both real and virtual
patients (Figure 4). Most patients with high Vmax or low
KmG6P appeared to have similarly high initial GSH/GSSG
levels as well as similarly high amounts of change, whereas
patients with low Vmax and high KmG6P, showed a broad
rangeofvaluesforinitialGSH/GSSGandamountsofchange,
and a greater proportion of patients with low values for these
indicators.Inthevirtualpatients,recoverytimewasinversely
associated with Vmax and positively associated with KmG6P
overall. Patients with high Vmax or low KmG6P tended to have
short, similar times of recovery of around 200s, whereas the
recovery times in patients with low Vmax or high KmG6P were
distributed between 200s to 700s. Several virtual patients
did not conform to these trends: for example, patients with
ah i g hVmax but requiring a relatively long recovery time.
Simulation of virtual patient data was performed 15
times to ensure that there was no bias when determining the
overall trend of the virtual patients. The degree of dispersion
diﬀered slightly between the trial runs; however, the traits
given above were present in all results.
3.4. Analysis of the Relative Impact of Vmax and KmG6P on the
Determination of Symptom Severity. We then examined the
relationship of Vmax and KmG6P with initial GSH/GSSG,
recovery time, and amount of change by constructing a 3-di-
mensional plot (Figure 5). The distribution of the graphs for
initial GSH/GSSG and amount of change were very similar.
When Vmax was low (Vmax < 10), higher values of KmG6P
were associated with lower initial GSH/GSSG, lower amount
of change, and longer recovery time.
4. Discussion
Deﬁciency in G6PD activity, and hence a disturbance in
redox homeostasis, can lead to severe complications during
the induction of an oxidative agent if not properly diagnosed
(e.g., [25, 26]). Therefore, the preclinical assessment of the
degree of metabolic dysfunction in a patient undergoing
oxidative stress has been the focus of many past studies of
G6PD deﬁciency [20, 27–29]. Although there have been
several studies aiming at the mathematical representation
and simulation of the metabolism in patients with G6PD
deﬁciency [20, 30–32], no studies have sought to interpret6 Advances in Hematology
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Figure 4:ComparisonofG6PDkineticparametersandsteadystatevalue,recoverytime,andamountofchangeinGSH/GSSGinindividuals.
(a) The relationship between Vmax and KmG6P and the evaluation criteria in real patients (Table 1). Dark gray dots represent G6PD-deﬁcient
patients, and the light gray dots represents the control. (b) The relationship between Vmax and KmG6P and the evaluation criterions in virtual
G6PDpatientscreatedfromrandomlyselectedparameters(Table 2).RecoverytimedenotesthetimerequiredfortheGSH/GSSGtoreturnto
itsinitialvalueafterperturbation,andamountofchangeiscalculatedby (2)inthetext.Notethatafewpatientsexhibitingabnormalrecovery
time (>30min, 0.4% the of original number of patients) have been eliminated from the plot. The data displayed here were obtained from
a single simulation run, which was representative of 15 simulation runs.
the pathways for drug-induced ROS production or deter-
mine the kinetic properties that make G6PD-deﬁcient RBCs
suﬀer exceptionally from critical redox imbalance after acute
exposuretoanoxidativeagent.Inthisstudy,weexaminedthe
metabolic changes in G6PD-deﬁcient RBCs during exposure
to H2O2 using a model that reproduced the oxidative-stress
removal mechanism and evaluated how the alterations in
redox homeostasis depend on the combination of kinetic pa-
rameters for enzymatic reactions in a patient’s RBCs.
The time course metabolite data showed a decrease in
GSH/GSSG and NADPH/NADP, and an increase in G6PD
activity during the exposure to H2O2 in all patients, but each
to a diﬀerent extent. Such behavior accurately represented
the antioxidant mechanism of H2O2 detoxiﬁcation by G6PD,
resulting in depletion of GSH, rapid production of GSSG,
and a subsequent decrease of NADPH, as has been shown
in previous experiments [33]. The similarity in CAT and
GSHpxactivityamongpatients,independentofthedegreeof
deﬁciency of the G6PD enzyme, agrees with previous obser-
vations of normal levels of antioxidant enzymes such as CAT
and GSHpx in G6PD-deﬁcient patients, independent of their
hemolytic crisis history [34, 35]. The increase in CAT and
GSHpx activity in conditions where oxidative stress is suﬃ-
ciently increased has also been shown in experimental data
[34, 36]. Furthermore, CAT has been recognized to have
a predominant role in the removal of ROS [37], which
explainstherelativelyhighactivationofCATseeninoursim-
ulation results. Although oxidative stress-induced changes
were present in the levels of all metabolites and antioxidant
enzyme activity, initial levels were restored shortly after the
perturbation, supporting previous observations implying
thatRBCmetabolismisnotdramaticallyaﬀectedbythedeﬁ-
ciency of G6PD enzyme activity [38].
Schuster et al. [20] proposed that the severity of clinical
symptoms in G6PD-deﬁcient individuals could be assessed
based on the maximal ﬂux stimulated by an oxidative sub-
stance and upper oxidative load boundaries. However, we
focused on the time-course restoration of GSH/GSSG; a
redoxcouplethathasbeenwidelyacceptedasareliableindex
in the estimation of cellular redox status [39]. Simulation
results predicted the presence of two types of behavior in the
recovery of GSH/GSSG among patients. Patients 1, 4, and 8
showed opposite traits to those of the other patients, with
a change in GSH/GSSG that was relatively low in magnitude,
but required long periods of time for recovery. In the control
patient, GSH/GSSG dropped rapidly but recovered quickly,
suggesting ﬂexibility in the adaption to sudden change.
One might expect that oxidative stress would decrease
GSH/GSSG with greater magnitude in patients with severe
G6PD deﬁciency than those who are relatively healthy; how-
ever, in this case we found that GSH/GSSG greatlydeclined
in the healthy control. The indication of sensitivity to stressAdvances in Hematology 7
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Figure 5: Correlation analysis of patient Vmax, KmG6P, and GSH/GSSG behavior. The ﬁgure shows GSH/GSSG behavior under ﬁxed values
for KmNADP, KiNADPH, KiATP, Ki2,3BPG, and independent variables for Vmax and KmG6P. Vmax values within the range 0–64, and even values of
KmG6P within the range 0–200, were plotted against initial GSH/GSSG (left panel), recovery time (middle panel), and amount of change
(right panel).
being greater in the control patient in terms of magnitude
was similar to the result of a previous report made by Arese
et al. [27], who showed that oxidative divicine strongly stim-
ulated the pentose phosphate pathway in normal RBCs, but
hardly aﬀected the metabolism in deﬁcient cells. We spec-
ulated that the reason for the minimal amount of change
of GSH/GSSG in patients 1, 4, and 8 is the patients’ initial
GSH/GSSG (Table 3, Figure 6). Patients 1, 4, and 8 displayed
not only the longest recovery times but also the lowest initial
GSH/GSSG. It is plausible that in RBCs where the initial
GSH/GSSG is very low, if GSH/GSSG were to decrease
greatly, the RBC could not function. We consider that the
antioxidant mechanisms in the RBC may act to lessen the
magnitude of GSH/GSSG reduction in such situations, and
the recovery time may be lengthened as a result. Also from
the accepted knowledge that cells with normal G6PD activity
are highly capable of maintaining a steady GSH/GSSG [40],
and redox imbalance in the RBC triggers the oxidant dam-
age of lipids and proteins of the membrane and thus destruc-
tion of the RBC [40, 41], we propose that patients exhibiting
a long recovery time of GSH/GSSG (i.e., severe redox
imbalance) are the most severe and susceptible to hemolytic
crises. Hence it can be concluded that patients 1, 4, and
8, which exhibit long recovery time and the small initial
GSH/GSSG; opposite qualities of the healthy control, are
the utmost severe G6PD-deﬁcient patients who suﬀer severe
clinical symptoms during the intake of an oxidative sub-
stance.Althoughtherearenoclinicaldescriptions ofpatients
4 and 8, it has been noted that patient 1 was diagnosed
with severe chronic nonspherocytic hemolytic anemia [20],
supporting our classiﬁcation of patient 1 as a severe pa-
tient.
The expansion of simulation to include virtual patients
with parameters randomly selected from a range of existing
values provided a broader view of the traits in patients, sim-
plifying the discovery of trends and enabling the prediction
of susceptibility to oxidative stressin patients from their ki-
netic parameters (Supplementary Figure 4). The indicators
of redox imbalance in patients were independent of the ki-
netic parameters in most graphs; however, those with Vmax
and KmG6P as the x-axis, showed sign of a trait (Figure 4).
Although patients with high Vmax (Vmax > 40) and those
with low KmG6P (KmG6P < 40) showed similarly high recovery
abilities, as Vmax decreased and KmG6P increased, the propor-
tion of patients with low initial GSH/GSSG, long recovery
time, and small amounts of change increased. These ﬁndings
suggest that low Vmax and high KmG6P enhance the likelihood
of a patient having severe clinical symptoms during intake
of an oxidative agent. From our observation that there were
patients exhibiting short recovery time even in the low-Vmax
and high-KmG6P groups, we can assume that the severity
of symptoms cannot be determined by one single kinetic
parameter.Alsoduringsimulation,afewvirtualpatients(not
shown in Figure 4) exhibited abnormallylong recovery times
that were longer than the test period, and so had a similar
recovery proﬁle to that of patient 1. Because we have linked
a mild decrease of GSH/GSSG and long recovery time with
severe disorder in redox homeostasis in patients following
a hemolytic crisis, we assume that these virtual patients
correspond to the most severe patients.8 Advances in Hematology
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Figure 6: Comparison of time course GSH/GSSG behavior in
healthy subject (above) and patient 1 (below). GSH/GSSG is given
as the concentration of GSH relative to GSSG at steady state.
The results of the kinetic parameter analysis of virtual
patients using a 3D image plot (Figure 5) led us to predict
that in the subset of patients with low Vmax, increases in
KmG6P will be associated with increases in the severity of the
patients’ symptoms. These results agree with past proposals
of low Vmax and high KmG6P association with clinical severity
of G6PD patients [16, 42, 43]. In fact, many patients with
such properties have been classiﬁed into the most severe
class of G6PD deﬁciency (i.e., Class I [5]) during diagnosis
[16]. However, in this study, there were numerous virtual
patients with low Vmax that showed high capabilities of de-
toxifying oxidative stress. This contradicts the principal clas-
siﬁcation of G6PD-deﬁcient patients [5], which mainly
groups patients according to the Vmax of the G6PD enzyme.
The method of randomly choosing parameters, used here,
is likely responsible for this disagreement. In this process,
acombinationofparametersthatarenotbiologicallyfeasible
may have been produced, resulting in abnormal results. For
example, an earlier work proposed that a low aﬃnity to
NADP may be linked to low inhibition by NADPH, ATP, and
2,3BPG [21]; however, in our simulation method, this was
not taken in account.
5. Conclusion
In conclusion, we successfully constructed a dynamic model
to represent the metabolic alterations in G6PD-deﬁcient
RBCs during exposure to oxidative stress induced by H2O2.
We conclude that low initial GSH/GSSG is linked with mild
decrease and delay in the recovery of the steady state GSH/
GSSG after induction of an oxidative agent, and patients
having this trait are susceptible to severe clinical symptoms.
Furthermore, we conclude that recovering abilities do not
rely on a single kinetic parameter such as Vmax. Our simu-
lation results predicted a higher redox imbalance following
oxidative damage in patients with low Vmax and high KmG6P.
In a disorder with more than 400 biochemical variants
exhibiting distinct clinical manifestations [3, 29], in which
the quick screening of a large number of patients requires
complicated and expensive tests that may give abnormal
results [13, 44, 45], in silico experiments such as those pre-
sented here will likely be signiﬁcant for the accessible
prediction of severity in pathophysiological conditions in
patients without actual in vivo experimental procedures. We
anticipate that our studies will also provide novel insights
that will facilitate the implementation of mathematical anal-
ysis and simulation for better patient diagnosis in the future.
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